International guidelines have recommended routine immunohistochemical staining (IHC) of all NSCLC for diagnosis, histologic subtype and molecular testing for EGFR mutation, and EML4-ALK fusion for patients with advanced NSCLC (18–20). Here, EML4 is linked to non-small cell lung carcinoma.